Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baucus Re-Introduces Comparative Effectiveness Bill, Adds “Safeguards” Between CER And Coverage Decisions

This article was originally published in The Pink Sheet Daily

Executive Summary

Finance Committee chairman would require opportunity for stakeholder comments, consideration of other research before CER results are used to revise HHS health coverage policy.

You may also be interested in...



PCORI In Brief: New Board Member, Funding Opportunities

The Patient-Centered Outcomes Research Institute welcomes UCSF professor Alicia Fernandez to the board, announces pragmatic trials funding opportunity; Senate bids farewell to PCORI champion Max Baucus.

CER Just “A Piece Of The Pie” In Driving Quality, Cost-Efficient Care

With the emphasis that is being given to comparative effectiveness research in the context of the current health care reform debate, industry stakeholders are cautioning that while it is a component of overall reform, it is not going to be a silver bullet that will drive lower costs

CER Just “A Piece Of The Pie” In Driving Quality, Cost-Efficient Care

With the emphasis that is being given to comparative effectiveness research in the context of the current health care reform debate, industry stakeholders are cautioning that while it is a component of overall reform, it is not going to be a silver bullet that will drive lower costs

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel